HC Wainwright Upgrades Monte Rosa Therapeutics (NASDAQ:GLUE) to “Strong-Buy”

Monte Rosa Therapeutics (NASDAQ:GLUE) was upgraded by analysts at HC Wainwright to a “strong-buy” rating in a research report issued to clients and investors on Thursday, Zacks reports.

Several other brokerages have also weighed in on GLUE. TD Cowen raised Monte Rosa Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. Wedbush reaffirmed an “outperform” rating and set a $27.00 price target on shares of Monte Rosa Therapeutics in a research report on Wednesday, September 9th. Guggenheim reiterated a “buy” rating and set a $28.00 price target on shares of Monte Rosa Therapeutics in a research note on Tuesday, August 25th. JPMorgan Chase & Co. decreased their price objective on Monte Rosa Therapeutics from $31.00 to $27.00 and set an “overweight” rating for the company in a report on Friday, August 7th. Finally, Zacks Research upgraded Monte Rosa Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 4th. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Monte Rosa Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $28.00.

Monte Rosa Therapeutics Stock Performance

NASDAQ GLUE opened at $11.26 on Thursday. The company has a market capitalization of $960.59 million, a PE ratio of -6.40 and a beta of 1.37. Monte Rosa Therapeutics has a 52-week low of $7.24 and a 52-week high of $25.77. The company has a 50-day simple moving average of $14.88 and a 200 day simple moving average of $17.76.

Monte Rosa Therapeutics (NASDAQ:GLUE) last released its earnings results on Thursday, August 6th. The company reported ($0.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). The company had revenue of $8.97 million for the quarter, compared to the consensus estimate of $12.91 million. Monte Rosa Therapeutics had a negative net margin of 560.85% and a negative return on equity of 43.31%. As a group, analysts forecast that Monte Rosa Therapeutics will post -1.04 EPS for the current fiscal year.

Insiders Place Their Bets

In other Monte Rosa Therapeutics news, insider Sharon Townson sold 6,000 shares of Monte Rosa Therapeutics stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $23.31, for a total transaction of $139,860.00. Following the completion of the transaction, the insider owned 67,845 shares of the company’s stock, valued at $1,581,466.95. The trade was a 8.13% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 6.40% of the stock is owned by insiders.

Hedge Funds Weigh In On Monte Rosa Therapeutics

A number of large investors have recently modified their holdings of GLUE. Allworth Financial LP purchased a new stake in Monte Rosa Therapeutics during the second quarter valued at about $30,000. SG Americas Securities LLC boosted its holdings in shares of Monte Rosa Therapeutics by 18.5% in the 1st quarter. SG Americas Securities LLC now owns 20,468 shares of the company’s stock worth $337,000 after purchasing an additional 3,189 shares in the last quarter. Seven Fleet Capital Management LP bought a new position in shares of Monte Rosa Therapeutics during the 4th quarter valued at about $63,000. Strs Ohio raised its holdings in shares of Monte Rosa Therapeutics by 18.3% during the 1st quarter. Strs Ohio now owns 42,700 shares of the company’s stock valued at $702,000 after buying an additional 6,600 shares in the last quarter. Finally, E Fund Management Co. Ltd. purchased a new position in shares of Monte Rosa Therapeutics during the 2nd quarter valued at about $200,000. 79.96% of the stock is currently owned by institutional investors.

Monte Rosa Therapeutics News Summary

Here are the key news stories impacting Monte Rosa Therapeutics this week:

• Positive Sentiment: Positive Phase 1 results: MRT-8102 produced robust and sustained NEK7 degradation at all tested once-daily doses. In obese participants with elevated cardiovascular risk, several disease-related biomarkers—including HMGB1, calprotectin, S100A12, serum amyloid A and IL-1?—fell to levels comparable with those observed in healthy volunteers. Monte Rosa Announces Positive MRT-8102 GFORCE-1 Results
• Positive Sentiment: Favorable safety profile: Four weeks of treatment and four weeks of follow-up produced no serious adverse events, adverse-event rates comparable with placebo, and no evidence of increased infection risk. Monte Rosa plans Phase 2 studies in coronary artery disease, gout and hidradenitis suppurativa. Monte Rosa Plans Mid-Stage Trials for MRT-8102
• Positive Sentiment: New analyst support: HC Wainwright initiated coverage with a Buy rating and a $25 price target, providing additional external validation of Monte Rosa’s molecular-glue platform and development pipeline. HC Wainwright Initiates Coverage
• Neutral Sentiment: The data measure biomarker normalization rather than clinical cardiovascular outcomes. Investors will likely focus on whether Phase 2 trials confirm efficacy, durability and safety in larger patient populations.
• Negative Sentiment: The weaker share performance suggests some investors may be taking profits or adopting a more cautious view after the initial data reaction, particularly because MRT-8102 remains an early-stage asset and Phase 2 execution will require additional time and funding.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics, Inc is a clinical-stage biotechnology company focused on developing medicines that selectively eliminate disease-causing proteins. The company uses its proprietary molecular glue degrader platform to identify small molecules that recruit targeted proteins to the cell’s natural protein-disposal machinery, potentially addressing proteins that have been difficult to treat with conventional drugs.

Monte Rosa’s pipeline is centered primarily on autoimmune and inflammatory diseases, as well as other serious conditions.